Citations

Clear

959 citation(s) found for "Service, F J".

Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper
Perucca, Emilio , French, Jacqueline A. , Aljandeel, Ghaieb , Balestrini, Simona , Braga, Patrícia , Burneo, Jorge G. , Charway‐Felli, Augustina , Cross, J. Helen , Galanopoulou, Aristea S. , Jain, Satish , Jiang, Yuwu , Kälviäinen, Reetta , Lim, Shih Hui , Meador, Kimford J. , Mogal, Zarine , Nabbout, Rima , Sofia, Francesca , Triki, Chahnez , Walker, Matthew C. , Wiebe, Samuel , Wilmshurst, Jo M. , Yacubian, Elza Márcia Targas , Kapur, Jaideep , Felli, Augustina Charway , Somerville, Ernest , Sperling, Michael R , Triki, Chahnez , Trinka, Eugen , Walker, Matthew C , Wiebe, Samuel , Wilmshurst, Jo M , Wirrell, Elaine C , Yacubian, Elza Márcia , Kapur, Jaideep , Galanopoulou, Aristea , Cross, Helen J , Perucca, Emilio , French, Jacqueline , Balestrini, Simona , Meador, Kimford J , Burneo, Jorge G , Jain, Satish , Somerville, Ernest , Sperling, Michael R. , Trinka, Eugen , Wirrell, Elaine

Mayo Clinic

Epilepsia | January 27, 2024 | Volume: 65 | Issue: 3 | Pages: 533-541

10.1111/epi.17877 | PMID 38279786 Get It

Abstract A variety of terms, such as “antiepileptic,” “anticonvulsant,” and “antiseizure” have been historically applied to medications for the treatment of seizure disorders. Terminology is important because using terms that do not accurately reflect the action of specific treatments may result in a misunderstanding of their effects and inappropriate use. The present International League Against Epilepsy (ILAE) position paper used a Delphi approach to develop recommendations on English‐language terminology applicable to pharmacological agents currently approved for treating seizure disorders. There was consensus that these medications should be collectively named “antiseizure medications”. This term accurately reflects their primarily symptomatic effect against seizures and reduces the possibility of health care practitioners, patients, or caregivers having undue expectations or an incorrect understanding of the real action of these medications. The term “antiseizure” to describe these agents does not exclude the possibility of beneficial effects on the course of the disease and comorbidities that result from the downstream effects of seizures, whenever these beneficial effects can be explained solely by the suppression of seizure activity. It is acknowledged that other treatments, mostly under development, can exert direct favorable actions on the underlying disease or its progression, by having “antiepileptogenic” or “disease‐modifying” effects. A more‐refined terminology to describe precisely these actions needs to be developed.
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
Bantilan, Kurt S. , Smith, Alexandra N., Maurer, Matthew J. , Teruya‐Feldstein, Julie , Matasar, Matthew J. , Moskowitz, Alison J. , Straus, David J. , Noy, Ariela , Palomba, M. Lia , Horwitz, Steven M. , Portlock, Carol S., Nowakowski, Grzegorz S. , Moskowitz, Craig H. , Hamlin, Paul A , Cerhan, James R , Salles, Gilles A , Nowakowski, Grzegorz S , Zelenetz, Andrew D , Maurer, Matthew , Horwitz, Steven M , Matasar, Matthew , Noy, Ariela , Cerhan, James R. , Habermann, Thomas M. , Salles, Gilles , Zelenetz, Andrew D.

Mayo Clinic

Blood Advances | January 25, 2024 | Volume: 8 | Issue: 9 | Pages: 2172-2181

10.1182/bloodadvances.2023011408 | PMID 38271621 Get It

Abstract Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered the standard-of-care for patients with advanced-stage diffuse large B-cell lymphoma (DLBCL), despite findings that patients with nongerminal center B-cell like (non-GCB) have significantly worse outcome with this regimen. We evaluated the prognostic significance of baseline risk factors, including cell of origin (COO) classified by the Hans algorithm, within an alternative chemoimmunotherapy program. At Memorial Sloan Kettering Cancer Center (MSK), 151 patients with DLBCL received sequential R-CHOP induction and (R)-ICE (rituximab, ifosfamide, carboplatin, and etoposide) consolidation. Outcome analysis based on COO was validated with a propensity score–matched cohort treated with R-CHOP from the Mayo Clinic component of the Molecular Epidemiology Resource (MER). Among the patients with GCB (n = 69) and non-GCB (n = 69) at MSK, event-free survival (EFS) of non-GCB was superior to that of GCB (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.29-0.98). Overall survival (OS) demonstrated an association in the same direction but was not statistically significant (HR, 0.68; 95% CI, 0.33-1.42). Propensity score–matched patients from MSK (n = 108) demonstrated a small attenuation in the HRs for EFS (HR, 0.57; 95% CI, 0.27-1.18) and OS (HR, 0.76; 95% CI, 0.33-1.79) and were no longer statistically significant. In contrast, the matched MER cohort (n = 108) demonstrated an EFS association (HR, 1.17; 95% CI, 0.70-1.95) and OS association (HR, 1.13; 95% CI, 0.64-2.00) in the opposite direction, but were also not statistically significant. R-CHOP induction and (R)-ICE consolidation may overcome the negative prognostic impact of the non-GCB phenotype, per the Hans algorithm, and can be preferentially selected for this population. This trial was registered at www.ClinicalTrials.gov as #NCT00039195 and #NCT00712582.
Is right ventricular outflow tract epicardial substrate ablation the standard of care in high-risk Brugada syndrome?
Behr, Elijah R. , Conte, Giulio , Wilde, Arthur A.M. , Wilde, Arthur A M , Behr, Elijah Raphael , Conte, Giulio

Mayo Clinic

Europace | January 22, 2024 | Volume: 26 | Issue: 1 | Pages: No page available

10.1093/europace/euae020 | PMID 38252938 Get It

Latin American consensus on diagnosis of gastroesophageal reflux disease
Olmos, Jorge A. , Pandolfino, John E. , Piskorz, María , Zamora, Natalia , Díaz, Miguel A Valdovinos, García, Luis R. Valdovinos, Domingues, Gerson , Vesco, Eduardo, Rivas, Mariel Mejia, Ovalle, Luis Fernando Pineda , Cisternas, Daniel , Vela, Marcelo F. , Remes Troche, José M , Vela, Marcelo F , Cisternas, Daniel , Guzmán, Mauricio, Hani, Albis Cecilia , García, Luis R Valdovinos, Pitanga‐Lukashok, Hannah , Vesco, Eduardo

Mayo Clinic

Neurogastroenterology & Motility | January 16, 2024 | Volume: 36 | Issue: 3 | Pages: No page available

10.1111/nmo.14735 | PMID 38225792 Get It

AbstractBackgroundDiagnosing gastroesophageal reflux disease (GERD) can be challenging given varying symptom presentations, and complex multifactorial pathophysiology. The gold standard for GERD diagnosis is esophageal acid exposure time (AET) measured by pH‐metry. A variety of additional diagnostic tools are available. The goal of this consensus was to assess the individual merits of GERD diagnostic tools based on current evidence, and provide consensus recommendations following discussion and voting by experts.MethodsThis consensus was developed by 15 experts from nine countries, based on a systematic search of the literature, using GRADE (grading of recommendations, assessment, development and evaluation) methodology to assess the quality and strength of the evidence, and provide recommendations regarding the diagnostic utility of different GERD diagnosis tools, using AET as the reference standard.Key ResultsA proton pump inhibitor (PPI) trial is appropriate for patients with heartburn and no alarm symptoms, but nor for patients with regurgitation, chest pain, or extraesophageal presentations. Severe erosive esophagitis and abnormal reflux monitoring off PPI are clearly indicative of GERD. Esophagram, esophageal biopsies, laryngoscopy, and pharyngeal pH monitoring are not recommended to diagnose GERD. Patients with PPI‐refractory symptoms and normal endoscopy require reflux monitoring by pH or pH‐impedance to confirm or exclude GERD, and identify treatment failure mechanisms. GERD confounders need to be considered in some patients, pH‐impedance can identify supragrastric belching, impedance‐manometry can diagnose rumination.ConclusionsErosive esophagitis on endoscopy and abnormal pH or pH‐impedance monitoring are the most appropriate methods to establish a diagnosis of GERD. Other tools may add useful complementary information.
Guidance for assessment of the inflammation etiologic criterion for the GLIM diagnosis of malnutrition: A modified Delphi approach
Jensen, Gordon L. , Cederholm, Tommy , Ballesteros‐Pomar, María D. , Correia, María Isabel Toulson Davisson , Cuerda, Cristina , Evans, David C. , Fukushima, Ryoji , Ochoa, Juan B. , González, Marı́a Cristina , Gossum, A. Van , Hartono, Joseph, Manzanares, William , McMahon, M. Molly , Mendez, Yolanda , Muscaritoli, Maurizio , Nogales, Guillermo Contreras , Nyulasi, Ibolya , Phillips, Wendy , Pirlich, Matthias , Pisprasert, Veeradej , Winkler, Marion F. , Compher, Charlene , Barazzoni, Rocco , Blaauw, Renee , Gautier, Juan B Ochoa , Cuerda, Cristina , Evans, David C , Fukushima, Ryoji , Gautier, Juan Bernardo Ochoa , Gonzalez, M Cristina , Gramlich, Leah , Heymsfield, Steven B , Jager-Wittenaar, Harriët , Jayatissa, Renuka , Keller, Heather , Malone, Ainsley , Manzanares, William , Mendez, Yolanda , Mogensen, Kris M , Mori, Naoharu , Muscaritoli, Maurizio , Nogales, Guillermo Contreras , Pisprasert, Veeradej , Rothenberg, Elisabet , de van der Schueren, Marian , Shi, Han Ping , Steiber, Alison , Winkler, Marion F , Compher, Charlene , Gramlich, Leah , Heymsfield, Steven B. , Malone, Ainsley , Mogensen, Kris M.

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | January 15, 2024 | Volume: 48 | Issue: 2 | Pages: 145-154

10.1002/jpen.2590 | PMID 38221842 Get It

Abstract Background The Global Leadership Initiative on Malnutrition (GLIM) approach to malnutrition diagnosis is based on assessment of three phenotypic (weight loss, low body mass index, and reduced skeletal muscle mass) and two etiologic (reduced food intake/assimilation and disease burden/inflammation) criteria, with diagnosis confirmed by fulfillment of any combination of at least one phenotypic and at least one etiologic criterion. The original GLIM description provided limited guidance regarding assessment of inflammation, and this has been a factor impeding further implementation of the GLIM criteria. We now seek to provide practical guidance for assessment of inflammation. Methods A GLIM‐constituted working group with 36 participants developed consensus‐based guidance through a modified Delphi review. A multiround review and revision process served to develop seven guidance statements. Results The final round of review was highly favorable, with 99% overall “agree” or “strongly agree” responses. The presence of acute or chronic disease, infection, or injury that is usually associated with inflammatory activity may be used to fulfill the GLIM disease burden/inflammation criterion, without the need for laboratory confirmation. However, we recommend that recognition of underlying medical conditions commonly associated with inflammation be supported by C‐reactive protein (CRP) measurements when the contribution of inflammatory components is uncertain. Interpretation of CRP requires that consideration be given to the method, reference values, and units (milligrams per deciliter or milligram per liter) for the clinical laboratory that is being used. Conclusion Confirmation of inflammation should be guided by clinical judgment based on underlying diagnosis or condition, clinical signs, or CRP.
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Maura, Francesco , Rajanna, Arjun Raj , Ziccheddu, Bachisio , Poos, Alexandra M. , Derkach, Andriy , Maclachlan, Kylee , Durante, Michael , Diamond, Benjamin , Papadimitriou, Marios , Davies, Faith E. , Boyle, Eileen M. , Walker, Brian A. , Hultcrantz, Malin , Silva, Ariosto, Hampton, Oliver , Teer, Jamie K. , Siegel, Erin M. , Bolli, Niccolò , Jackson, Graham , Kaiser, Martin , Cook, Gordon , Kazandjian, Dickran , Stein, Caleb, Chesi, Marta , Bergsagel, Leif, Elias, K. , Goldschmidt, Hartmut , Fenk, Roland , Rhee, Fritz Van, Usmani, Saad Z. , Shain, Kenneth H. , Weinhold, Niels , Bergsagel, P. Leif , Bergsagel, P. Leif , Davies, Faith E , Walker, Brian A , Jackson, Graham H , Pawlyn, Charlotte , Cook, Gordon , Kazandjian, Dickran , Chesi, Marta , Mai, Elias K , Goldschmidt, Hartmut , Weisel, Katja C , Fenk, Roland , Raab, Marc S , van Rhee, Frits , Usmani, Saad , Shain, Kenneth H , Weinhold, Niels , Landgren, C Ola , Bolli, Niccolo' , Boyle, Eileen M , Kaiser, Martin F , Maura, Francesco , Durante, Michael , Maclachlan, Kylee , Derkach, Andriy , Diamond, Benjamin T , Pawlyn, Charlotte , Stein, Caleb, Raab, Marc S. , Morgan, Gareth J. , Landgren, Ola

Mayo Clinic

Journal of Clinical Oncology | January 9, 2024 | Volume: 42 | Issue: 11 | Pages: 1229-1240

10.1200/jco.23.01277 | PMID 38194610 Get It

PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS To decipher and predict the molecular and clinical heterogeneity of NDMM, we assembled a series of 1,933 patients with available clinical, genomic, and therapeutic data. RESULTS Leveraging a comprehensive catalog of genomic drivers, we identified 12 groups, expanding on previous gene expression–based molecular classifications. To build a model predicting individualized risk in NDMM (IRMMa), we integrated clinical, genomic, and treatment variables. To correct for time-dependent variables, including high-dose melphalan followed by autologous stem-cell transplantation (HDM-ASCT), and maintenance therapy, a multi-state model was designed. The IRMMa model accuracy was significantly higher than all comparator prognostic models, with a c-index for OS of 0.726, compared with International Staging System (ISS; 0.61), revised-ISS (0.572), and R2-ISS (0.625). Integral to model accuracy was 20 genomic features, including 1q21 gain/amp, del 1p, TP53 loss, NSD2 translocations, APOBEC mutational signatures, and copy-number signatures (reflecting the complex structural variant chromothripsis). IRMMa accuracy and superiority compared with other prognostic models were validated on 256 patients enrolled in the GMMG-HD6 (ClinicalTrials.gov identifier: NCT02495922 ) clinical trial. Individualized patient risks were significantly affected across the 12 genomic groups by different treatment strategies (ie, treatment variance), which was used to identify patients for whom HDM-ASCT is particularly effective versus patients for whom the impact is limited. CONCLUSION Integrating clinical, demographic, genomic, and therapeutic data, to our knowledge, we have developed the first individualized risk-prediction model enabling personally tailored therapeutic decisions for patients with NDMM.
Comorbid neurotrauma increases neurodegenerative-relevant cognitive, motor, and autonomic dysfunction in patients with rapid eye movement sleep behavior disorder: a substudy of the North American Prodromal Synucleinopathy Consortium
Ligman, Brittany R. , Bryant‐Ekstrand, Mohini , Keil, Allison , Powers, Katherine , Olivo, Cosette, Neilson, Lee E. , Pelletier, Amélie , Gagnon, Jean‐François , Liu, Lang , Forsberg, Leah K. , Fields, Julie A. , Ross, Owen A. , Howell, Michael J. , McLeland, Jennifer , Criswell, Susan R. , Miglis, Mitchell G. , Lee‐Iannotti, Joyce , Ju, Yo‐El S. , Lim, Miranda M. , Locke, Jessica, Amudson-Huffmaster, Sommer, Brushaber, Nellie, Chung, Jae Woo , Kam, Joshua De , Fischbach, Ellen, Ekelmans, Adrian , Keane, Marissa, Kraft, Ruth, MacKinnon, Colum D. , Miner-Rose, Daeva, Murphy, Samantha , Rivera, Adreanne, Sanchez, Sarahmay, Summers, Rebekah L. S. , Tiegan, Luke, Taylor, Leah, Timm, Paul, Tucker, Kelsey, Yu, Erik, Tran, Peter , Galasko, Douglas, Mignot, Emmanuel , Elliott, Jonathan E , Powers, Katherine , Neilson, Lee E , Gan-Or, Ziv , St Louis, E K , Ross, Owen A , Huddleston, Daniel E , Bliwise, Donald L , Avidan, Alon Y , Criswell, Susan R , During, Emmanuel , Miglis, Mitchell G , Boeve, Brad , Lim, Miranda M , Howell, Michael J , Elliott, Jonathan E. , Postuma, Ronald B. , Gan‐Or, Ziv , Yu, Eric , Louis, Erik K. St. , Huddleston, Daniel E. , Bliwise, Donald L. , Avidan, Alon Y. , Schenck, Carlos H. , Videnovic, Aleksandar , Shprecher, David , Boeve, Bradley F. , Duff, Kevin , Choudhury, Parichita , Stauder, Matthew J. , Taylor, Leah

Mayo Clinic

SLEEP | January 4, 2024 | Volume: 47 | Issue: 6 | Pages: No page available

10.1093/sleep/zsae007 | PMID 38181205 Get It

Abstract Study Objectives Rapid eye movement sleep behavior disorder (RBD) is strongly associated with phenoconversion to an overt synucleinopathy, e.g. Parkinson’s disease (PD), Lewy body dementia, and related disorders. Comorbid traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD)—henceforth “neurotrauma” (NT)—increase the odds of RBD by ~2.5-fold and are associated with an increased rate of service-connected PD in Veterans. Thus, RBD and NT are both independently associated with PD; however, it is unclear how NT influences neurological function in patients with RBD. Methods Participants ≥18 years with overnight polysomnogram-confirmed RBD were enrolled between 8/2018 to 4/2021 through the North American Prodromal Synucleinopathy Consortium. Standardized assessments for RBD, TBI, and PTSD history, as well as cognitive, motor, sensory, and autonomic function, were completed. This cross-sectional analysis compared cases (n = 24; RBD + NT) to controls (n = 96; RBD), matched for age (~60 years), sex (15% female), and years of education (~15 years). Results RBD + NT reported earlier RBD symptom onset (37.5 ± 11.9 vs. 52.2 ± 15.1 years of age) and a more severe RBD phenotype. Similarly, RBD + NT reported more severe anxiety and depression, greater frequency of hypertension, and significantly worse cognitive, motor, and autonomic function compared to RBD. No differences in olfaction or color vision were observed. Conclusions This cross-sectional, matched case:control study shows individuals with RBD + NT have significantly worse neurological measures related to common features of an overt synucleinopathy. Confirmatory longitudinal studies are ongoing; however, these results suggest RBD + NT may be associated with more advanced neurological symptoms related to an evolving neurodegenerative process.
Multiscale spatial mapping of cell populations across anatomical sites in healthy human skin and basal cell carcinoma
Gânier, Clarisse , Herrera-Oropeza, Gabriel, Du-Harpur, Xinyi , Blakeley, Matthew , Gabriel, Jeyrroy , Predeus, Alexander V. , Prete, Martin , Harun, Nasrat, Darrigrand, Jean-François , Haiser, Alexander , Wyles, Saranya P. , Teichmann, Sarah A. , Wyles, Saranya, Watt, Fiona M , Mazin, Pavel , Çakır, Batuhan , Shaw, Tanya J. , Haniffa, Muzlifah A. , Lynch, Magnus

Mayo Clinic

Proceedings of the National Academy of Sciences | January 2, 2024 | Volume: 121 | Issue: 2 | Pages: No page available

10.1073/pnas.2313326120 | PMID 38165934 Get It

Our understanding of how human skin cells differ according to anatomical site and tumour formation is limited. To address this, we have created a multiscale spatial atlas of healthy skin and basal cell carcinoma (BCC), incorporating in vivo optical coherence tomography, single-cell RNA sequencing, spatial global transcriptional profiling, and in situ sequencing. Computational spatial deconvolution and projection revealed the localisation of distinct cell populations to specific tissue contexts. Although cell populations were conserved between healthy anatomical sites and in BCC, mesenchymal cell populations including fibroblasts and pericytes retained signatures of developmental origin. Spatial profiling and in silico lineage tracing support a hair follicle origin for BCC and demonstrate that cancer-associated fibroblasts are an expansion of a POSTN + subpopulation associated with hair follicles in healthy skin. RGS5+ pericytes are also expanded in BCC suggesting a role in vascular remodelling. We propose that the identity of mesenchymal cell populations is regulated by signals emanating from adjacent structures and that these signals are repurposed to promote the expansion of skin cancer stroma. The resource we have created is publicly available in an interactive format for the research community.
Abstract 15441: Impact of the COVID-19 Pandemic on Cardiac Implantable Electronic Device Procedures and Complications in the United States
Carver, Caleb , Ramphul, Kamleshun , Obeng‐Gyimah, Edmond, Schuler, Brian, Sawatari, Hiroyuki , Wafa, Syed Emir Irfan , Padmanabhan, Deepak , Deshpande, Saurabh , Khan, Hassan , Ahmed, Raheel , Khanji, Mohammed Y , Somers, Virend K. , Providência, Rui , Chahal, C. Anwar A.

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.15441 Get It

Introduction: The impact of COVID-19 was felt across cardiology as resources were redirected to critical care, delaying elective cardiology procedures. Hypothesis: To evaluate differences in outcomes of cardiac implantable electronic device (CIED) procedures in 2020 (height of COVID) vs. 2016-2019 (pre-COVID). Methods: Adults >= 18 years undergoing CIED procedures were identified from National Inpatient Sample Databases (NIS) 2016-2020. Complications and mortality were assessed based on the type of device: Permanent Pacemaker (PPM); Implantable Cardioverter Defibrillator (ICD); Cardiac Resynchronization Therapy with Pacemaker (CRT-P) or defibrillator (CRT-D): Leadless PPM; Generator explant (GE), and Lead extraction (LE). Results: A 13.8% drop in CIED admissions was recorded between 2019 and 2020 (p<0.01). Fewer procedures involving PPM, ICD, CRT-P, CRT-D, LE, and GE were observed between 2019 and 2020. Leadless PPM utilization rose consistently between 2016-2020 (47.6% increase during 2020 vs 2019)(Figure). In 2020, a higher proportion of patients were classified with a Charlson Comorbidity Index score of ≥3 (severe) (47.4% in 2020 vs. 42.9% in 2016-2019, p<0.01). The table shows significantly higher complications during CIED implants with no changes in mortality related to procedures. Conclusions: Patients admitted for CIED implants in 2020 had more severe comorbidities and expressed considerable differences in complications than pre-COVID era (2016-2019), but mortality remained unchanged. Leadless PPM use increased during pandemic, as against a decrease in the use of other CIEDs.
Abstract 15432: Racial and Sex Disparities in Age-Adjusted Mortality in COVID-19 Patients With Atrial Fibrillation in the United States
Carver, Caleb , Ramphul, Kamleshun , Salloum, Mohammad N. , Obeng‐Gyimah, Edmond, Schuler, Brian, Wafa, Syed Emir Irfan , Padmanabhan, Deepak , Deshpande, Saurabh , Khan, Hassan , Ahmed, Raheel , Agboola, Olayinka, Khanji, Mohammed Y , Sawatari, Hiroyuki , Somers, Virend K. , Providência, Rui , Chahal, C. Anwar A.

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.15432 Get It

Introduction: While Coronavirus disease 2019 (COVID-19) primarily affects the respiratory system but can impact the cardiovascular system can triggering various complications. Hypothesis: To investigate the trend in age-adjusted mortality rates (AAMRs) in patients with atrial fibrillation(AF) among COVID-19-positive patients (CPP) by race and sex. Methods: Trends in AAMRs (per 100,000) from all-cause in patients with AF between April to December 2016-2020 were evaluated via the National Inpatient Sample and the US Census Bureau. The AAMRs among CPP with AF in 2020 was also evaluated between racial and sex cohorts. Results: A gradual rise in AAMR(all causes) in patients with AF was observed between 2016-2019, with a 49.4% overall rise between 2019(271 per 100,000) and 2020(405 per 100,000) ( Table 1a and Figure ). Around 250475 COVID-19-positive patients had AF, and 24.2% of cases did not survive their hospitalization (vs. 10.9% in those without AF, p<0.01, aOR 1.457, 95% CI 1.438-1.477). Among CPP males and females with AF that died, White females and males were the oldest, while Black males and females reported the highest mean Charlson Comorbidity Index (CCI) score ( Table 1b ).Furthermore, among the CPP with AF in 2020, Hispanics reported a higher AAMR (119.6 per 100,000) than Whites(111.1 per 100,000) and Blacks(101.9 per 100,000). AAMRs in males were higher in Hispanic males (144.8 per 100,000), followed by White males (129.7 per 100,000), and Black males (110 per 100,000). However, the AAMRs in females were highest in Black females (91.3 per 100,000), followed by White females (88.3 per 100,000) and Hispanic females (87.0 per 100,000). ( Table 1c ) Conclusions: AAMRs in patients with AF are on the rise and a sharp growth was seen during the first year of the pandemic. AAMRs among CPP patients with AF were highest among Black females and Hispanic males, while White males and females were oldest and Black males and females reported the highest CCI scores.